Shilpa Medicare has announced that it has received approval from the Subject Expert Committee (Haematology) to conduct Phase III clinical trials for its Recombinant Human Albumin (rHA) 20%. This development marks a significant step forward in addressing the growing demand for albumin in various medical treatments.
rHA 20% is derived from yeast and is designed to be a highly purified, structurally, and functionally equivalent alternative to human serum albumin. Human serum albumin is typically sourced from whole blood or donated human plasma, which can lead to supply limitations. Shilpa Medicare's rHA aims to overcome these limitations by providing a consistent and reliable source of this critical protein.
Clinical Significance of Recombinant Human Albumin
Albumin plays a vital role in numerous medical applications, including restoring blood volume, replacing lost fluids during accidents, treating serious burn injuries, managing fatal erythroblastosis, addressing hypoproteinemia, and supporting patients undergoing surgeries. The consistent availability of rHA 20% could significantly improve patient care in these scenarios.
"The approval to conduct Phase III clinical trials is a pivotal moment for Shilpa Medicare," stated a company spokesperson. "We believe that rHA 20% has the potential to address the critical need for albumin in India and globally, ensuring a stable supply for patients who depend on it."
Shilpa Medicare's Expanding Portfolio
In related news, Shilpa Medicare's subsidiary, Shilpa Pharma Lifesciences, recently secured a Certificate of Suitability (CEP) from a European drug regulator for Nifedipine, an active pharmaceutical ingredient (API) used in hypertension treatment. Nifedipine, a calcium-channel blocker, is prescribed as an antihypertensive and anti-anginal medication, reducing blood pressure and alleviating chest pain by relaxing blood vessels and improving blood flow to the heart.
